Free Trial

Fulcrum Therapeutics (FULC) Competitors

Fulcrum Therapeutics logo
$8.75 -0.24 (-2.67%)
Closing price 10/13/2025 04:00 PM Eastern
Extended Trading
$8.75 0.00 (0.00%)
As of 10/13/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FULC vs. OCUL, ANIP, VERA, TWST, DYN, APGE, COGT, TLRY, ABCL, and IMCR

Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.

Fulcrum Therapeutics vs. Its Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Fulcrum Therapeutics (NASDAQ:FULC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Ocular Therapeutix presently has a consensus target price of $22.63, suggesting a potential upside of 90.93%. Fulcrum Therapeutics has a consensus target price of $9.60, suggesting a potential upside of 9.71%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, research analysts clearly believe Ocular Therapeutix is more favorable than Fulcrum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Fulcrum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Fulcrum Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Fulcrum Therapeutics' return on equity of -31.05% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-382.51% -71.92% -49.36%
Fulcrum Therapeutics N/A -31.05%-28.96%

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fulcrum Therapeutics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$63.72M32.36-$193.51M-$1.28-9.26
Fulcrum Therapeutics$80M5.92-$9.73M-$1.22-7.17

Ocular Therapeutix has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the S&P 500.

In the previous week, Ocular Therapeutix had 9 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 21 mentions for Ocular Therapeutix and 12 mentions for Fulcrum Therapeutics. Ocular Therapeutix's average media sentiment score of 0.59 beat Fulcrum Therapeutics' score of 0.50 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fulcrum Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Fulcrum Therapeutics beats Ocular Therapeutix on 11 of the 17 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FULC vs. The Competition

MetricFulcrum TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$486.28M$3.36B$6.05B$10.30B
Dividend YieldN/A2.31%5.73%4.82%
P/E Ratio-7.1722.0885.1927.10
Price / Sales5.92478.69597.83133.24
Price / CashN/A44.9825.7730.18
Price / Book1.9410.3812.626.69
Net Income-$9.73M-$52.47M$3.32B$276.55M
7 Day Performance-5.30%0.18%-0.04%-0.40%
1 Month Performance25.00%13.95%8.73%6.53%
1 Year Performance145.10%20.83%78.10%41.04%

Fulcrum Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FULC
Fulcrum Therapeutics
1.1679 of 5 stars
$8.75
-2.7%
$9.60
+9.7%
+151.4%$486.28M$80M-7.17100
OCUL
Ocular Therapeutix
3.9143 of 5 stars
$10.97
-3.9%
$22.13
+101.7%
+21.2%$1.99B$56.66M-8.57230
ANIP
ANI Pharmaceuticals
3.9623 of 5 stars
$92.06
+2.7%
$97.29
+5.7%
+55.1%$1.95B$614.38M-119.56600
VERA
Vera Therapeutics
2.3088 of 5 stars
$30.94
+2.7%
$63.00
+103.6%
-28.6%$1.92BN/A-8.6440
TWST
Twist Bioscience
3.7818 of 5 stars
$31.85
+2.5%
$48.90
+53.5%
-32.2%$1.88B$312.97M-21.97990
DYN
Dyne Therapeutics
3.5623 of 5 stars
$12.65
-3.1%
$34.07
+169.3%
-58.3%$1.86BN/A-3.28100Gap Down
APGE
Apogee Therapeutics
3.0639 of 5 stars
$39.82
-0.2%
$92.63
+132.6%
-5.2%$1.84BN/A-9.6491
COGT
Cogent Biosciences
1.9402 of 5 stars
$15.90
+0.9%
$20.00
+25.8%
+44.0%$1.79BN/A-8.9380High Trading Volume
TLRY
Tilray Brands
2.4454 of 5 stars
$1.58
-2.5%
$1.94
+22.6%
+3.7%$1.78B$210.48M-0.682,842Earnings Report
Analyst Upgrade
Gap Up
ABCL
AbCellera Biologics
2.3909 of 5 stars
$5.87
-0.5%
$8.00
+36.3%
+118.9%$1.76B$28.83M-10.67500
IMCR
Immunocore
2.2825 of 5 stars
$34.01
-0.6%
$56.89
+67.3%
+4.1%$1.72B$310.20M-85.03320

Related Companies and Tools


This page (NASDAQ:FULC) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners